Orient Europharma Co (ROCO:4120) E10: NT$1.39 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4120 Orient Europharma Co Ltd ROCO:4120
60 GF Score
Price NT$44.40
GF Value NT$44.98
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Orient Europharma Co E10?

Orient Europharma Co ROCO:4120 +0.91% 60 E10 is NT$1.39 as of Dec. 2025. GuruFocus rates ROCO:4120 with a GF Score™ of 60/100 and a GF Value™ of NT$44.98 (Fairly Valued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Orient Europharma Co's adjusted earnings per share data for the three months ended in Dec. 2025 was NT$-2.760. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is NT$1.39 for the trailing ten years ended in Dec. 2025.

During the past 12 months, Orient Europharma Co's average E10 Growth Rate was -40.30% per year. During the past 3 years, the average E10 Growth Rate was -25.60% per year. During the past 5 years, the average E10 Growth Rate was -17.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Orient Europharma Co was -3.80% per year. The lowest was -25.60% per year. And the median was -11.50% per year.

As of today (2026-07-22), Orient Europharma Co's current stock price is NT$44.40. Orient Europharma Co's E10 for the quarter that ended in Dec. 2025 was NT$1.39. Orient Europharma Co's Shiller PE Ratio of today is 31.94.

During the past 13 years, the highest Shiller PE Ratio of Orient Europharma Co was 34.55. The lowest was 8.51. And the median was 13.89.


Orient Europharma Co  (ROCO:4120) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Orient Europharma Co's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=44.40/1.39
=31.94

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Orient Europharma Co was 34.55. The lowest was 8.51. And the median was 13.89.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Orient Europharma Co E10 Related Terms


Orient Europharma Co E10 Historical Data

* Premium members only.

The historical data trend for Orient Europharma Co's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orient Europharma Co E10 Chart

Orient Europharma Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.82 3.37 2.88 2.33 1.39

Orient Europharma Co Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.33 1.99 1.92 1.72 1.39

ROCO:4120 vs ZTS, UTHR: E10 Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Orient Europharma Co's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Orient Europharma Co Shiller PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Orient Europharma Co's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Orient Europharma Co's Shiller PE Ratio falls into.


ROCO:4120
60GF Score
Orient Europharma Co Ltd ROCO:4120
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Orient Europharma Co E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Orient Europharma Co's adjusted earnings per share data for the three months ended in Dec. 2025 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Dec. 2025 (Change)*Current CPI (Dec. 2025)
=-2.76/324.0540*324.0540
=-2.760

Current CPI (Dec. 2025) = 324.0540.

Orient Europharma Co Quarterly Data

per share eps CPI Adj_EPS
201603 1.990 238.132 2.708
201606 0.860 241.018 1.156
201609 0.940 241.428 1.262
201612 1.590 241.432 2.134
201703 2.010 243.801 2.672
201706 1.240 244.955 1.640
201709 1.870 246.819 2.455
201712 0.150 246.524 0.197
201803 1.540 249.554 2.000
201806 0.110 251.989 0.141
201809 0.970 252.439 1.245
201812 0.210 251.233 0.271
201903 1.490 254.202 1.899
201906 0.620 256.143 0.784
201909 0.360 256.759 0.454
201912 0.380 256.974 0.479
202003 1.360 258.115 1.707
202006 1.480 257.797 1.860
202009 -0.150 260.280 -0.187
202012 -0.390 260.474 -0.485
202103 0.070 264.877 0.086
202106 -0.080 271.696 -0.095
202109 -0.540 274.310 -0.638
202112 1.930 278.802 2.243
202203 0.270 287.504 0.304
202206 -1.120 296.311 -1.225
202209 -2.160 296.808 -2.358
202212 -0.570 296.797 -0.622
202303 0.320 301.836 0.344
202306 -2.180 305.109 -2.315
202309 -0.400 307.789 -0.421
202312 3.920 306.746 4.141
202403 -1.040 312.332 -1.079
202406 -0.810 314.175 -0.835
202409 0.130 315.301 0.134
202412 -1.550 315.605 -1.591
202503 -1.770 319.799 -1.794
202506 -0.530 322.561 -0.532
202509 -1.490 324.800 -1.487
202512 -2.760 324.054 -2.760

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of NT$1.39 mean?
Orient Europharma Co (ROCO:4120) has a E10 of NT$1.39 as of Dec. 2025. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Orient Europharma Co and its competitors.
Is Orient Europharma Co's E10 too high?
Orient Europharma Co's current E10 is NT$1.39. Overall, Orient Europharma Co has a GF Score™ of 60/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Orient Europharma Co's E10 compare to ZTS and UTHR?
Orient Europharma Co's E10 of NT$1.39 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Drug Manufacturers company?
A good E10 depends on the Drug Manufacturers industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Orient Europharma Co and its competitors. Orient Europharma Co's current E10 is NT$1.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orient Europharma Co stock overvalued right now?
Based on GuruFocus' analysis, Orient Europharma Co (ROCO:4120) is currently considered Fairly Valued. The stock's GF Value™ is NT$44.98, compared to a current price of NT$44.40 — trading 1.3% below its estimated fair value. The current E10 is NT$1.39. Orient Europharma Co's overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Orient Europharma Co (ROCO:4120), the current E10 is NT$1.39 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Orient Europharma Co (ROCO:4120) Overvalued in 2026?

Based on GuruFocus' analysis, Orient Europharma Co stock appears to be undervalued. The current stock price of NT$44.40 is trading 1.3% below its estimated GF Value™ of NT$44.98. GuruFocus considers Orient Europharma Co to be Fairly Valued.

Key valuation signals for ROCO:4120:

  • E10: NT$1.39
  • GF Value™: NT$44.98 vs. price of NT$44.40 (1.3% below fair value)
  • GF Score™: 60/100 with 4 warning signs

No single metric tells the full story. See the ROCO:4120 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Orient Europharma Co Business Description

Address 13th Floor, No. 128, Chengde Road, Section 6, Beitou District, Taipei, TWN, 112052
Orient Europharma Co Ltd is a Taiwan-based company engaged in the wholesale of Western Pharmaceutical and Medical Devices. The firm also manufactures drugs and medicines, Beverages, Cleaning Preparations, Cosmetics, Medical Devices, and Other Food Products. Its products cover various therapeutic areas, including the central nervous system, cardiovascular, diabetes, allergy, cosmetics, and health supplements. The company's segments include: Western Pharma BU which includes manufacture and sale of pharmaceutical and cosmetic products; and Nutricare BU includes sale of various nutrition supplements and consumable healthcare products. It derives maximum revenue from Western Pharma BU segment. Geographically, it operates in Taiwan, China, and Southeast Asia.
60GF Score

Get the complete analysis for ROCO:4120

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$44.40
Price
NT$44.98
GF Value